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or almost two decades, HIV infection has been a
progressive disease leading to early morbidity and
mortality for more than a million Americans (Centers
for Disease Control and Prevention [CDC], 1998).
Although HIV infection strikes people of any age, it
continues to be a disease of young persons in relatively
good health. Persons with HIV (PWHIV) who are in
the advanced stages of the disease typically experience
very troubling symptoms. Insomnia is one of these
bothersome symptoms.
Recent advances in diagnosis and treatment of HIV
disease have resulted in a declining AIDS death rate
(Emini, 1996). The declining death rate is followed by
a substantial increase in the prevalence of AIDS. As of
June 1998, there were 352,379 men, women, and children living with HIV disease (CDC, 1998). With more
people living longer and doing better in the face of
HIV infection, management of symptoms such as
insomnia will be of even greater importance.
Insomnia refers to unsatisfactory duration, efficiency, or quality of sleep that is experienced 3 or more
nights per week (Morin, 1993). Luce and Segal (1969)
classified insomnia into the following three types:
problems with falling asleep, problems with staying
asleep, and problems with early awakening.
Sleep disturbance is a frequent symptom of HIV
infection (Cohen, Ferrans, Vizgirda, Kunkle, & Cloninger, 1996) that contributes to fatigue, disability,
eventual unemployment (Darko, Mitler, & Henriksen,
1995), and a decreased quality of life. Many symptoms
of HIV disease often lead to insomnia (Flaskerud &
Ungvarski, 1995). Organic brain diseases (Wiegand,
Moller, Schreiber, Krieg, & Holsboer, 1991), psychological factors (Norman, Chediak, Kiel, & Cohn,
1990), substance dependency (Flaskerud &

Ungvarski, 1995), and the side effects of many antiretroviral therapies and other drugs (Chohan, 1999) used
to treat HIV disease may produce insomnia. Although
helping the client manage sleep disturbance is of great
importance, available information in this area remains
modest.
Insomnia frequently begins prior to the diagnosis of
HIV, and it continues throughout the disease (Norman,
1990). In fact, daytime sleepiness may be a presenting
symptom of HIV disease (Norman et al., 1992). PWHIV
are more likely to be unemployed, feel fatigued throughout the day, sleep more, nap more, and have diminished alertness (Darko, McCutchan, Kripke, Gillin, &
Golshan, 1992). Fatigue and insomnia have been
found to contribute to mortality in PWHIV (Darko et
al., 1992). During polysomnography, sleep architecture changes have been noted in PWHIV in that deeper
sleep (Stages III and IV) is more prevalent in the last
half of the sleep period (Norman, 1990). Wiegand and
colleagues (1991) reported longer sleep onset latency,
reduced total sleep time, reduced sleep efficiency, and
more time spent awake in PWHIV. Ferini-Strambi and
colleagues (1995) reported significant reductions in
deeper sleep in PWHIV.

Physiological Factors
Related to Insomnia in HIV Disease
Neurotransmitters, opiate peptides, hormones, and
cytokines are important in regulating sleep. Issues
related to sleep and these physiological factors in HIV
disease will be presented. These endogenous substances are listed in Table 1.
Many changes occur in the hypothalamic-pituitaryadrenal axis (HPAA) in HIV infection. Central to these
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Table 1.

Endogenous Substances Important in the
Regulation of Sleep

Neurotransmitters

Opiate peptides
Hormones

Cytokines

Serotonin
Norepinephrine
Epinephrine
Acetylcholine
Histamine
Adenosine
Gamma-amino-butyric acid (GABA)
Endorphins
Enkephlins
Corticotropin Releasing Factor
Growth Hormone Releasing Factor
Growth Hormone
Adrenocorticotropin Hormone
Cortisol
Interleukin-1
Interleukin-6
Tumor necrosis factor

changes is the fact that the circadian rhythm of the
HPAA is lost in PWHIV (Rondanelli et al., 1997).
Growth hormone (GH) is important in the regulation of sleep. GH decreases in PWHIV. GH secretion
increases slow-wave sleep (SWS) and decreases the
number of awakenings (Astrom, Christensen, Gjerris, &
Trojaborg, 1991; Astrom & Lindholm, 1990). GH
administration may be useful to treat the wasting syndrome in PWHIV (Hellerstein, Kohn, Mudie, &
Viteri, 1990; Jenkins & Ross, 1999). The effects of
GH administration on sleep in PWHIV need to be
tested.
Corticotropin-releasing factor (CRF) secretion
increases in HIV disease (Azar & Melby, 1993). It has
been suggested that interleukin-1-β (IL-1-β) may be
responsible for the increase in CRF (Sapolsky, Rivier,
Yamamoto, Plotsky, & Vale, 1987). Increased secretion of CRF is associated with lighter sleep, decreased
time in SWS, and increased time spent in Stage I and
Stage II sleep (Holsboer, von Bardeleben, & Steiger,
1988).
In turn, CRF stimulates the production of adrenocorticotropin hormone (ACTH). Increased secretion
of ACTH reduces rapid eye movement (REM) sleep
and reduces total sleep time (Born, Spath-Schwalbe,
Schwakenhofer, Kern, & Fehm, 1989).
ACTH stimulates the secretion of cortisol. Profound hypercortisolemia is characteristic in the early

stages of HIV disease, but hypocortisolemia is
observed in the later stages of the disease. HIV replication is enhanced by cortisol (Markham, Salahuddin,
Veren, Orndorff, & Gallo, 1986). Hypercortisolemia is
related to increased wakefulness, lighter sleep, and
reduced REM sleep (Born et al., 1986).
Three cytokines have been shown to produce sleep.
These cytokines, IL-1-β, interleukin-6 (IL-6), and
tumor-necrosis factor alpha (TNF-α), are markers of
immune activation. These cytokines are elevated in the
blood of PWHIV, and they are associated with an
increase in HIV replication and the progression of the
disease.
IL-1-β stimulates the production of CRF and may
contribute to the hypercortisolemia that is seen in HIV
disease (Azar & Melby, 1993). IL-1-β increases total
sleep time and non-REM (NREM), and decreases
REM and SWS (Borbely & Tobler, 1989). However, in
HIV disease, increased secretion of IL-1-β may lead to
insomnia because of its effects on CRF.
IL-6 stimulates the production of ACTH and cortisol concentrations. IL-6 decreases SWS in the first half
of the sleep period, but it increases SWS in the second
half (Spath-Schwalbe et al., 1998).
TNF-α increases NREM sleep, decreases REM
sleep (Graf, Heller, Sakaguchi, & Krishna, 1987),
increases SWS (Kapas & Krueger, 1996), and
increases total sleep time (Graf et al., 1987). In
PWHIV, TNF-α elevates to as much as six times the
normal level. Significant relationships are seen
between TNF-α and delta-wave sleep in HIV infection; increased delta-wave sleep and sleep fragmentation are seen early in the infection and decreased
delta-wave sleep appear in advanced HIV disease
(Darko, Miller, et al., 1995). This raises the question
that IL-6 may indirectly lead to insomnia through the
HPAA.
It is impossible for the clinician to address these
diverse physiological alterations in the immune and
endocrine systems. Being aware of these changes and
intervening when possible is essential. For instance,
vigilant monitoring and treatment for concurrent
infections may decrease the level of immune system
activation and viral replication. In that regard, it is
important to remember the importance of monitoring
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disease progression, optimizing antiretroviral therapy,
and assisting the client to adhere to treatment regimens, all of which are important aspects in the treatment of insomnia.

Symptoms Related to
Insomnia in HIV Disease
Sleep promotion requires adequate control of other
HIV-related symptoms. Anxiety and depression are
related to sleep quality. Symptoms produced as a result
of opportunistic infection and opportunistic malignancy (i.e., pain, abdominal cramping, diarrhea,
incontinence, itching, burning, fever, night sweats,
cough, and dyspnea) contribute to the sleeplessness
experienced by PWHIV (Lashley, 1999).
Restoring restful sleep depends on effective management of other HIV-related symptoms. This may be
where clinicians can be most effective in restoring and
promoting sleep. As an example, managing the anxiety and depression that often accompany HIV infection and insomnia are very beneficial to promoting
sleep. Benzodiazepines are useful in treating anxiety,
but they must be used with great caution for patients
who are concurrently taking protease inhibitors.
Short-acting benzodiazepines are sometimes prescribed for individuals who have trouble falling
asleep. Intermediate-acting benzodiazepines are
employed when the person has trouble staying asleep.
Long-acting benzodiazepines may be useful for those
who are experiencing significant anxiety in addition to
the insomnia. Sedating antidepressants such as nortriptyline, buspirone, or trazadone may help with the
insomnia (Weilburg, 1995). Likewise, management of
other related symptoms is just as essential when planning and implementing interventions to promote
sleep.

Pharmacological Factors
Related to Insomnia in HIV Disease
Many of the drugs used to treat HIV infection and
its complications have insomnia as a side effect. A
number of the nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors,
protease inhibitors, and the drugs used to treat opportunistic malignancies significantly impact sleep.

Table 2.

Medications and Sleep in HIV Disease

Organisms
targeted
HIV

95

Drug

Effect on
sleep

Didanosine (ddI)
Lamivudine (3TC)

Insomnia
Insomnia
Sleep disorders
Stavudine (d4T)
Insomnia
Zalcitabine (ddC)
Insomnia
Zidovudine (AZT, ZDV) Insomnia
Somnolence
Delavirdine
Insomnia
Nevirapine
None reported
Indinavir
Insomnia
Somnolence
Nelvinavir mesylate
Insomnia
Sleep disorders
Somnolence
Ritonavir
Insomnia
Somnolence
Saquinavir
None reported
Viruses
Acyclovir
None reported
Foscarnet
Insomnia
Somnolence
Ganciclovir
Somnolence
Pneumocystis carinii Atovaquone
Insomnia
Clindamycin
None reported
Dapsone
Insomnia
Pentamidine
None reported
Primaquine
None reported
Trimethoprimsulfamethoxazole
None reported
Trimetrexate
None reported
Mycobacterium
tuberculare
Ethambutol
None reported
Isonizid
None reported
Pyrazinamide
None reported
Rifampin
Drowsiness
Mycobacterium
avium
Azithromycin
Somnolence
Ciprofloxacin
Insomnia
Somnolence
Clarithromycin
None reported
Clofazimine
None reported
Ofloxacin
Insomnia
Sleep disorders
Rifabutin
None reported
Fungi
Amphoteracin B
None reported
Fluconazole
None reported
Flucytosine
Sedation
Itraconazole
Somnolence
Ketoconazole
Somnolence
SOURCE: Adapted from Chohan (1999).

These drugs are presented in Table 2. Reduction of
viral load results in less immune and endocrine
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activation that may lead to better quality of sleep.
There are no other alternatives for many of these
drugs; however, altering administration times may be
beneficial in promoting sleep. In cases where there is
another suitable drug that is less of a detriment to
sleep, that drug might be considered.
Other factors related to insomnia include the use of
sedatives (i.e., alcohol, benzodiazepines, barbiturates,
and narcotics) and the use of stimulants (i.e., coffee,
tea, cola, and chocolate). Many over-the-counter
medications and alternative therapies may produce
insomnia. Assessment of these factors may help the
clinician to identify factors that may be disrupting
sleep. Once such factors have been identified, the clinician will be able to counsel the patient regarding
their effects on sleep.
Insomnia is a serious problem for the PWHIV in
that, for many individuals, it is severe enough to drastically diminish the quality of life that they experience.
Nursing’s holistic perspective of patient care places
nurse clinicians in a unique position to address the
symptoms of HIV disease. Insomnia is a prime example in which a holistic approach is needed, for it is
impossible to improve sleep quality without addressing the many other symptoms that are experienced by
PWHIV. A careful history of the patient who is sleeping poorly may identify physiological, psychological,
and environmental factors that will allow nurses to
effectively intervene and improve sleep quality. Combining western pharmacological therapies and
complementary therapies may optimize rest for these
sleepless individuals. What the PWHIV needs is
problem-solving care based on careful assessment and
sound scientific data. Not only are these factors important to clinicians and the care that they provide, but
these factors provide many research questions that
remain unanswered. Clinicians and researchers have
the opportunity to work collaboratively to find and
validate effective interventions that can promote sleep
and decrease the adverse effects of insomnia for
patients with HIV/AIDS.
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